
Human Cellular tumor antigen p53 210-218, RPILTIITL
Description
About Human Cellular tumor antigen p53 210-218, RPILTIITL
The Human Cellular tumor antigen p53 Peptide (IEDB: 440098) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Cellular tumor antigen p53 Peptide, H-RPILTIITL-OH (Uniprot: P04637 aa: 210-218) from JPT is produced under strict quality control and quality management.
Human Cellular tumor antigen p53 210-218, RPILTIITL - Specifications
- Peptide sequence: H-RPILTIITL-OH
- Amount: 10 mg (10 x 1 mg)
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Lung cancer
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Custom Peptide Synthesis!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for Human Cellular tumor antigen p53 210-218, RPILTIITL
References:
Read References with JPT’s Antigen Peptides
Human Cellular tumor antigen p53 210-218, RPILTIITL has been described in:
Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non-small cell lung cancers., Sci Adv, 2021 (PMID: 34138742)
Comprehensive Analysis of the Naturally Processed Peptide Repertoire: Differences between HLA-A and B in the Immunopeptidome., PLoS One, 2015 (PMID: 26375851)
Generation of novel complete HLA class I monoallelic cell lines used in an MHC stabilization assay for neoantigen evaluation., Oncol Lett, 2023 (PMID: 37415627)
Documentation
Documentation for Human Cellular tumor antigen p53 210-218, RPILTIITL
Properties
Properties of Human Cellular tumor antigen p53 210-218, RPILTIITL
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Lung cancer |
Layout: | Freeze-dried in glass vial |
Organism: | Human |
Protein Name: | Cellular tumor antigen p53 |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to Human Cellular tumor antigen p53 210-218, RPILTIITL
Information | Values |
---|---|
Sequence: | H-RPILTIITL-OH |
Specifications: | 9mer peptide as TFA salt |